$50M Awarded to MD Anderson to Support Research
The University of Texas MD Anderson Cancer Center has been awarded $30 million to support research, core facilities, recruitment and prevention efforts from the Cancer Prevention and Research Institute of Texas (CPRIT). An additional $19.9 million was awarded to a company co-founded by MD Anderson to support the development of a novel targeted therapy to treat neurological conditions caused by chemotherapy. In total, MD Anderson and its projects received 28 percent of the $177 million in awards announced by CPRIT.
MD Anderson awards included $11.9 million for multi-investigator research including awards for breast cancer and pre-clinical studies; $12.5 million for core facilities support; $4 million for new faculty recruitment; $1.3 million for cancer prevention; and $200,000 for high-impact high-risk research. CPRIT awarded $19.9 million to Korysso Therapeutics, Inc., doing business as Magnolia Tejas Corporation, the wholly owned Houston-based subsidiary of Magnolia Neurosciences Corporation, launched by MD Anderson and Accelerator Life Science Partners.
“These CPRIT awards are vital to our mission as they allow us to fund transformational research and prevention projects, to recruit stellar talent and to more quickly advance novel therapeutics developed by our experts,” said Stephen Hahn, M.D., chief medical executive of MD Anderson. “We’re grateful to CPRIT and the people to Texas for this much-needed support that will help us work to improve the treatment and prevention of cancer for our patients and beyond.”
Since its inception, CPRIT has awarded $2.15 billion in grants for cancer research, of which MD Anderson and its projects have received $428 million, or nearly 20 percent. The agency began making awards in 2009 after Texas voters overwhelmingly approved a 2007 constitutional amendment committing $3 billion to the fight against cancer. Programs made possible with CPRIT funding have reached Texans from all 254 counties of the state, brought 159 distinguished researchers to Texas, advanced scientific and clinical knowledge, and provided more than 4.7 million life-saving education, training, prevention and early detection services to Texans.
“CPRIT has reached a significant milestone, which is only possible due to the support of Texans, their elected representatives, and our partner institutions and grantees,” said Wayne Roberts, CPRIT chief executive officer. “As a result of this historical undertaking, Texas is developing into a world class center of cancer research and prevention as our state’s institutions grow in international prominence.”
This article has been republished from materials provided by The University of Texas MD Anderson Cancer Center . Note: material may have been edited for length and content. For further information, please contact the cited source.
Anticipatory timing is controlled by two clocks in the brain, one dependent on memories from past experiences and the other on rhythm. Both are critical to our ability to navigate and enjoy the world. New research shows the neural networks supporting each of these timekeepers are split between two different parts of the brain, depending on the task at hand.READ MORE
International Conference on Clinical Trials & Pharmacovigilance
Feb 28 - Mar 01, 2019